Antimicrobial and DNA Gyrase-Inhibitory Activities of Novel Clorobiocin Derivatives Produced by Mutasynthesis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 4, 2004, Pages 1307-1312

  Galm, Ute ^a   Heller, Stefanie ^b   Shapiro, Stuart ^b   Page, Malcolm ^b   Li, Shu Ming ^a   Heide, Lutz ^a  

^a Pharmazeutisches Institut   (Germany)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 4,7 DIHYDROXYCOUMARIN; 3 DIMETHYLALLYL 4 HYDROXYBENZOYL DERIVATIVE; AMIDE; CARBOXYLIC ACID; CLOROBIOCIN; COUMARIN DERIVATIVE; DESCLOROBIOCIN DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; HYDROXYBENZOIC ACID DERIVATIVE; NOVIOSE; NOVOBIOCIN; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; ENZYME INHIBITION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; BACILLUS SUBTILIS; BACTERIA; DNA GYRASE; DNA, SUPERHELICAL; ENZYME INHIBITORS; MICROBIAL SENSITIVITY TESTS; MUTATION; NOVOBIOCIN; STREPTOMYCES;

EID: 1642461379     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.4.1307-1312.2004     Document Type: Article

References (41)

1. Cui, L., X. Ma, K. Sato, K. Okuma, F. C. Tenover, E. M. Mamizuka, C. G. Gemmell, M. N. Kim, M. C. Ploy, N. El Solh, V. Ferraz, and K. Hiramatsu. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14.
2. Eady, E. A., and J. H. Cove. 2003. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus - an emerging problem for the management of skin and soft tissue infections. Curr. Opin. Infect. Dis. 16:103-124.
3. El Falaha, B. M., A. D. Russell, and J. R. Furr. 1983. Sensitivities of wildtype and envelope-defective strains of Escherichia coli and Pseudomonas aeruginosa to antibacterial agents. Microbios 38:99-105.
4. Engel, H. W., N. Soedirman, J. A. Rost, W. J. van Leeuwen, and J. D. van Embden. 1980. Transferability of macrolide, lincomycin, and streptogramin resistances between group A, B, and D streptococci, Streptococcus pneumoniae, and Staphylococcus aureus. J. Bacteriol. 142:407-413.
5. Eustáquio, A. S., B. Gust, T. Luft, S.-M. Li, K. F. Chater, and L. Heide. 2003. Clorobiocin biosynthesis in Streptomyces: identification of the halogenase and generation of structural analogs. Chem. Biol. 10:279-288.
6. Ferroud, D., J. Collard, M. Klich, C. Dupuis-Hamelin, P. Mauvais, P. Lassaigne, A. Bonnefoy, and B. Musicki. 1999. Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-Rhamnose as an effective substitute for L-noviose. Bioorg. Med. Chem. Lett. 9:2881-2886.
7. Galm, U., M. A. Dessoy, J. Schmidt, L. A. Wessjohann, and L. Heide. In vitro and in vivo production of new aminocoumarins by a combined biochemical, genetic and synthetic approach. Chem. Biol., in press.
8. Hinman, J. W., E. L. Caron, and H. Hoeksema. 1957. Novobiocin. V. Carbamoyl migration and isonovobiocin. J. Am. Chem. Soc. 79:5321-5322.
9. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155.
10. 1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob. Agents Chemother. 22:662-671.
11. Jacobs, M. R., H. J. Koornhof, R. M. Robins-Browne, C. M. Stevenson, Z. A. Vermaak, I. Freiman, G. B. Miller, M. A. Witcomb, M. Isaacson, J. I. Ward, and R. Austrian. 1978. Emergence of multiply resistant pneumococci. N. Engl. J. Med. 299:735-740.
12. Jones, R. N. 1989. Should novobiocin be clinically re-evaluated? Diagn. Microbiol. Infect. Dis. 12:363-365.
13. Kieser, T., M. J. Bibb, M. J. Buttner, K. F. Chater, and D. A. Hopwood. 2000. Practical Streptomyces genetics. John Innes Foundation, Norwich, United Kingdom.
14. Kirby, W. M., D. G. Hudson, and W. D. Noyers. 1956. Clinical and laboratory studies of novobiocin, a new antibiotic. Arch. Intern. Med. 98:1-7.
15. Lafitte, D., V. Lamour, P. O. Tsvetkov, A. A. Makarov, M. Klich, P. Deprez, D. Moras, C. Briand, and R. Gilli. 2002. DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5′-methyl group of the noviose. Biochemistry 41:7217-7223.
16. Laurin, P., D. Ferroud, M. Klich, C. Dupuis-Hamelin, P. Mauvais, P. Lassaigne, A. Bonnefoy, and B. Musicki. 1999. Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B. Bioorg. Med. Chem. Lett. 9:2079-2084.
17. Laurin, P., D. Ferroud, L. Schio, M. Klich, C. Dupuis-Hamelin, P. Mauvais, P. Lassaigne, A. Bonnefoy, and B. Musicki. 1999. Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B. Bioorg. Med. Chem. Lett. 9:2875-2880.
18. Lewis, R. J., O. M. Singh, C. V. Smith, T. Skarzynski, A. Maxwell, A. J. Wonacott, and D. B. Wigley. 1996. The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography. EMBO J. 15:1412-1420.
19. Lewis, R. J., F. T. F. Tsai, and D. B. Wigley. 1996. Molecular mechanisms of drug inhibition of DNA gyrase. Bioessays 18:661-671.
20. Li, S.-M., L. Westrich, J. Schmidt, C. Kuhnt, and L. Heide. 2002. Methyltransferase genes in Streptomyces rishiriensis: new coumermycin derivatives from gene-inactivation experiments. Microbiology 148:3317-3326.
21. Li, X. Z., D. M. Livermore, and H. Nikaido. 1994. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob. Agents Chemother. 38:1732-1741.
22. Marchese, A., G. C. Schito, and E. A. Debbia. 2000. Evolution of antibiotic resistance in gram-positive pathogens. J. Chemother. 12:459-462.
23. Marcinak, J. F., and A. L. Frank. 2003. Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr. Opin. Infect. Dis. 16:265-269.
24. Maxwell, A. 1993. The interaction between coumarin drugs and DNA gyrase. Mol. Microbiol. 9:681-686.
25. Maxwell, A. 1997. DNA gyrase as a drug target. Trends Microbiol. 5:102-109.
26. Maxwell, A., and D. M. Lawson. 2003. The ATP-binding site of type II topoisomerases as a target for antibacterial drugs. Curr. Top. Med. Chem. 3:283-303.
27. Musicki, B., A. M. Periers, P. Laurin, D. Ferroud, Y. Benedetti, S. Lachaud, F. Chatreaux, J. L. Haesslein, A. Iltis, C. Pierre, J. Khider, N. Tessot, M. Airault, J. Demassey, C. Dupuis-Hamelin, P. Lassaigne, A. Bonnefoy, P. Vicat, and M. Klich. 2000. Improved antibacterial activities of coumarin antibiotics bearing 5′,5′-dialkylnoviose: biological activity of RU79115. Bioorg. Med. Chem. Lett. 10:1695-1699.
28. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
29. Peixoto, C., P. Laurin, M. Klich, C. Dupuis-Hamelin, P. Mauvais, P. Lassaigne, A. Bonnefoy, and B. Musicki. 2000. Synthesis of isothiochroman 2,2-dioxide and 1,2-benzooxathiin 2,2-dioxide gyrase B inhibitors. Tetrahedron Lett. 41:1741-1745.
30. Periers, A. M., P. Laurin, D. Ferroud, J. L. Haesslein, M. Klich, C. Dupuis-Hamelin, P. Mauvais, P. Lassaigne, A. Bonnefoy, and B. Musicki. 2000. Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere. Bioorg. Med. Chem. Lett. 10:161-165.
31. 1 and ciprofloxacin, alone or in combination. Antimicrob. Agents Chemother. 31:539-543.
32. Pitlik, S. 2003. Old drugs for new bugs. Br. Med. J. 326:235-236.
33. Pojer, F., S.-M. Li, and L. Heide. 2002. Molecular cloning and sequence analysis of the clorobiocin biosynthetic gene cluster: new insights into the biosynthesis of aminocoumarin antibiotics. Microbiology 148:3901-3911.
34. Pojer, F., E. Wemakor, B. Kammerer, H. Chen, C. T. Walsh, S.-M. Li, and L. Heide. 2003. CloQ, a prenyltransferase involved in clorobiocin biosynthesis. Proc. Natl. Acad. Sci. USA 100:2316-2321.
35. Raad, I., R. Darouiche, R. Hachem, M. Sacilowski, and G. P. Bodey. 1995. Antibiotics and prevention of microbial colonization of catheters. Antimicrob. Agents Chemother. 39:2397-2400.
36. Raad, I. I., R. Y. Hachem, D. Abi-Said, K. V. Rolston, E. Whimbey, A. C. Buzaid, and S. Legha. 1998. A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2. Cancer 82:403-411.
37. Reusser, F., and L. A. Dolak. 1986. Novenamine is the active moiety in novobiocin. J. Antibiot. 39:272-274.
38. Sasaki, T., Y. Igarashi, N. Saito, and T. Furumai. 2001. TPU-0031-A and B, new antibiotics of the novobiocin group produced by Streptomyces sp. TPA0556. J. Antibiot. 54:441-447.
39. Tsai, F. T., O. M. Singh, T. Skarzynski, A. J. Wonacott, S. Weston, A. Tucker, R. A. Pauptit, A. L. Breeze, J. P. Poyser, R. O'Brien, J. E. Ladbury, and D. B. Wigley. 1997. The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins 28:41-52.
40. Walsh, T. J., H. C. Standiford, A. C. Reboli, J. F. John, M. E. Mulligan, B. S. Ribner, J. Z. Montgomerie, M. B. Goetz, C. G. Mayhall, D. Rimland, D. A. Stevens, S. L. Hansen, G. C. Gerard, and R. J. Ragaul. 1993. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprimsulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob. Agents Chemother. 37:1334-1342.
41. Westrich, L., L. Heide, and S.-M. Li. 2003. CloN6, a novel methyltransferase catalysing the methylation of the pyrrole-2-carboxyl moiety of clorobiocin. Chembiochem 4:768-773.